Sydnexis, Inc.
Quick facts
Phase 3 pipeline
- SYD-101 0.01% · Diabetes
SYD-101 is a small molecule that targets the SGLT2 receptor. - SYD-101 0.03% · Dermatology/Infectious Disease
SYD-101 is a topical antifungal agent that disrupts fungal cell membrane integrity.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: